ZYC 300

Drug Profile

ZYC 300

Alternative Names: ZYC300

Latest Information Update: 03 May 2013

Price : $50

At a glance

  • Originator MGI Pharma Biologics
  • Developer Eisai Co Ltd
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (IM) prior to February 2013
  • 01 Feb 2011 Phase-I development is ongoing
  • 29 Jan 2008 Eisai acquires MGI PHARMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top